ERBB2 and cancer: In a retrospective case–control study of patients with HR+/HER2− MBC, a higher prevalence of bone and liver metastases was observed in ERBB2‐mutated cancers; this was not associated with a worse prognosis in terms of overall survival (OS) from metastatic disease [9].